IL6 and metastatic melanoma: Among patients with metastatic melanoma treated with immune checkpoint-blocking antibodies, IL-6 is a significant prognostic factor for survival: elevated baseline and on-treatment levels of IL-6 correlate with worsened overall survival across multiple randomized studies [103].